tiprankstipranks
Market News

AstraZeneca Shares Drop Despite Q3 Earnings Beat

Shares of AstraZeneca (AZN) declined 3.3% in Friday’s early hours, even though the global pharmaceutical company reported better-then-expected earnings for the third quarter.

Adjusted earnings of $1.08 topped the consensus estimate of $0.62 per share and increased 14% from the last year’s quarter.

Total revenues increased 50% year-over-year to $9.87 billion and matched the Street’s expectations. Notably, revenues excluding COVID-19 vaccine Alexion increased by 34% to $8.82 billion, primarily due to higher sales in R&I and Oncology disease related products.

See Top Smart Score Stocks on TipRanks >>

CEO of AstraZeneca, Pascal Soriot, said, “Our broad portfolio of medicines and diversified geographic exposure provides a robust platform for long-term sustainable growth. Following accelerated investment in upcoming launches after positive data flow, we expect a solid finish to the year and our earnings guidance is unchanged.”

Outlook

AstraZeneca projects Q4 total revenues to grow by a mid-to-high twenties percentage, while total revenue excluding the COVID-19 vaccine is expected to grow by a low-twenties percentage. Core ESP is expected to be in the range of $5.05 to $5.40 per share.

Analyst Recommendation

Based on the two Buy ratings assigned, the stock has a Moderate Buy consensus rating. The average AstraZeneca price target of $73 implies 16% upside potential from current levels. Shares have gained 12.6% over the past year.

Negative Investor Sentiment

TipRanks’ Stock Investors tool shows that investors currently have a Very Negative stance on AstraZeneca, with 48.7% of investors decreasing their exposure to AZN stock over the past 30 days.

Related News:
Biogen Gains 3.2% on Positive ADUHELM Phase 3 Data
Lordstown Motors Posts Lower-Than-Expected Q3 Loss; Shares Fall 10%
GrowGeneration Posts Upbeat Q3 Results; Street Says Buy

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More